Big Money Sentiment increased to 1.1 in 2018 Q4. It has change of 0.30, from 2018Q3’s 0.8. The ratio improved due to Supernus Pharmaceuticals, Inc. positioning: 29 sold and 76 reduced. 34 funds took holdings and 82 increased holdings. Investors holded 48.83 million in 2018Q3 but now own 49.20 million shares or 0.77% more.
663,951 are held by Voya Investment Mngmt Limited Liability Co. Kornitzer Management Incorporated Ks owns 107,509 shs or 0.07% of their US capital. 27,394 are owned by Lpl Financial Ltd Limited Liability Company. Ameritas Prtnrs has invested 0.01% in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Ftb Advsr Inc accumulated 554 shs. Braun Stacey Assoc invested in 0.28% or 107,221 shs. Provident Invest Mngmt Inc accumulated 563,504 shs or 3.34% of the stock. Castleark Mngmt Limited Liability Co holds 4,280 shs. D E Shaw And invested in 0% or 52,902 shs. 34,196 were reported by Texas Permanent School Fund. 16,334 were accumulated by Aperio Gru Limited Com. Marshall Wace Llp holds 423,964 shs. Jane Street Grp Inc Ltd Llc stated it has 54,591 shs or 0% of all its holdings. Regions Fincl invested 0% of its capital in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN). Cornerstone Advsr has 753 shs.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Ratings Coverage

In total 4 analysts cover Supernus Pharmaceuticals (NASDAQ:SUPN). “Buy” rating has 4, “Sell” are 0, while 0 are “Hold”. (NASDAQ:SUPN) has 100% bullish analysts. 9 are the (NASDAQ:SUPN)’s ratings reports on Apr 6, 2019 according to StockzIntelligence Inc. In Monday, March 4 report FBR Capital maintained it with “Buy” rating and $65 target. On Monday, December 17 the firm earned “Buy” rating by Mizuho. On Monday, November 12 the stock of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) earned “Buy” rating by FBR Capital. On Monday, February 25 FBR Capital maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) rating. FBR Capital has “Buy” rating and $65 target. On Wednesday, February 27 Cantor Fitzgerald maintained the shares of SUPN in report with “Buy” rating. On Wednesday, February 27 Mizuho maintained Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) with “Buy” rating. Listed here are Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) PTs and latest ratings.

29/03/2019 Broker: BidaskScore Rating: Sell Downgrade
04/03/2019 Broker: FBR Capital Rating: Buy New Target: $65 Maintain
27/02/2019 Broker: Mizuho Rating: Buy New Target: $63 Maintain
27/02/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $57 Maintain
25/02/2019 Broker: FBR Capital Rating: Buy New Target: $65 Maintain
22/02/2019 Broker: BidaskScore Rating: Sell Downgrade
17/12/2018 Broker: Mizuho Old Rating: Buy New Rating: Buy Old Target: $61 New Target: $63 Maintain
21/11/2018 Broker: SunTrust Rating: Buy New Target: $57.0000
12/11/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $68 New Target: $65 Maintain

SUPN is hitting $38.8 during the last trading session, after increased 1.38%.Currently Supernus Pharmaceuticals, Inc. is uptrending after 0.70% change in last April 6, 2018. SUPN has 480,266 shares volume. SUPN underperformed the S&P 500 by 3.67%.

Supernus Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States.The firm is valued at $2.03 billion. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.18.93 is the P/E ratio. The companyÂ’s product candidates comprise SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with attention deficit hyperactivity disorder ; and SPN-812, a viloxazine hydrochloride, which has completed Phase IIb trial that is used for the treatment of ADHD.

For more Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) news brought out briefly go to: Globenewswire.com, Seekingalpha.com, Seekingalpha.com, Nasdaq.com or Globenewswire.com. The titles are as follows: “Supernus Announces Record Full Year 2018 Financial Results – GlobeNewswire” brought out on February 26, 2019, “Supernus Pharmaceuticals Does Not Impress In ADHD – Seeking Alpha” on March 19, 2019, “Revisiting Supernus Pharmaceuticals – Seeking Alpha” with a publish date: September 27, 2018, “Noteworthy Tuesday Option Activity: AGO, SUPN, TDG – Nasdaq” and the last “Supernus to Present at the 2019 Cowen Health Care Conference – GlobeNewswire” with publication date: March 06, 2019.